Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
REGULATORY
Japan Inks COVAX Pact with Optional Arrangement, Commits 17.2 Billion Yen Upfront
The Japanese government on September 15 concluded a formal agreement to join the COVAX facility, a WHO-led global pact for the joint procurement of COVID-19 vaccines, with the Cabinet approving the same day an upfront payment of 17.2 billion yen…
To read the full story
Related Article
- Elite Team Working to Secure COVID-19 Vaccines; Indemnity to Be a Major Focus: Ex-MHLW Chief Medical Officer
October 8, 2020
- Japan to Officially Sign Up for COVAX Pact; Govt to Hammer Out Payment on Sept. 15
September 14, 2020
- Japan Weighs COVAX Participation with Optional Purchase Arrangement
September 2, 2020
- Japan Discussing Participation in COVAX Pact: Sr. Health Vice Minister
August 20, 2020
- Komeito Nudges Govt to Join COVAX Pact for Coronavirus Vaccine Procurement
August 19, 2020
REGULATORY
- FPMAJ Reports Detailed Results of Blanket Self-Inspections for Generic Firms
January 29, 2025
- Celltrion Is Developer of Japan’s Third Stelara Biosimilar in the Wings
January 29, 2025
- MHLW Donates Mpox Vaccine to Congo
January 28, 2025
- LDP-OK’ed Bill for PMD Act Amendment Specifies Launch of Innovative Drug Fund
January 28, 2025
- Opposition Party Member Calls for Chuikyo Reform
January 27, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…